LOGIN  |  REGISTER
Cue Biopharma
Astria Therapeutics

Progyny to Present at KeyBanc Life Sciences & MedTech Investor Forum

March 20, 2023 | Last Trade: US$14.35 0.37 2.65

NEW YORK, March 20, 2023 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a leading benefits management company specializing in fertility and family building benefits solutions, today announced that Pete Anevski, Progyny’s Chief Executive Officer, and Mark Livingston, Chief Financial Officer, will participate in a virtual fireside chat at the KeyBanc Life Sciences & MedTech Investor Forum on Tuesday, March 21, 2023, at 2:15 P.M. Eastern Time.

A live audiocast and replay will be available from the Events and Presentations section of Progyny’s website at http://investors.progyny.com.

About Progyny

Progyny (Nasdaq: PGNY) is a leading fertility benefits management company. We are redefining fertility and family building benefits, proving that a comprehensive and inclusive solution can simultaneously benefit employers, patients, and physicians.

Our benefits solution empowers patients with education and guidance from a dedicated Patient Care Advocate (PCA), provides access to a premier network of fertility specialists using the latest science and technologies, reduces healthcare costs for the nation’s leading employers, and drives optimal clinical outcomes. We envision a world where anyone who wants to have a child can do so.

Headquartered in New York City, Progyny has been recognized for its leadership and growth by CNBC Disruptor 50, Modern Healthcare’s Best Places to Work in Healthcare, Financial Times, INC. 5000, and Crain’s Fast 50 for NYC. For more information, visit www.progyny.com.

For Further Information, Please Contact:

Investors:
James Hart
This email address is being protected from spambots. You need JavaScript enabled to view it.

Media:
Selena Yang
This email address is being protected from spambots. You need JavaScript enabled to view it.

Chimerix

Stock Quote

Featured Stock

Immix Biopharma

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...

CLICK TO LEARN MORE

Featured Stock

ClearPoint Neuro

ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB